1995 was a very fine year: Performance pays off

It was a good year. Actually, it was a great year. Biotech companies in 1995 did just about everything biotech companies are supposed to do: they reported outstanding clinical data, they got products approved and they proved increasingly attractive to pharmaceutical companies, which stepped up to the plate for both alliances and acquisitions.

If 1994 seemed like the year of the failure - although it wasn't nearly as bad as the popular perception would have it (see BioCentury Jan. 3, 1995) - the last half of 1995 conversely may have left the impression that biotech could do no wrong...